Bispecific antibodies: a novel approach for targeting prominent biomarkers

References

• TThe Expresswire. Monoclonal antibodies market demand to grow at a CAGR of 8.5% during 2019-2025 – marketWatch [Internet]. 2019 Sep [ accessed 2019 Nov 22]. https://www.marketwatch.com/press-release/monoclonal-antibodies-market-demand-to-grow-at-a-cagr-of-85-during-2019-2025-2019-09-10.
   Google Scholar
• Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.
   Google Scholar
• Minh Ngoc Duong IS. Advances in bispecific antibodies engineering: novel concepts for immunotherapies. J Blood Disord Transfus. 2015;6:1000243.
   Google Scholar
• Pento JT. Monoclonal antibodies for the treatment of cancer. Anticancer Res [Internet]. 2017;37:5935–39 [accessed 2019 Sep 26]. http://www.ncbi.nlm.nih.gov/pubmed/29061772.
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. [Internet]. 1985;314:628–31. doi:10.1038/314628a0.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science [Internet]. 2008;321:974–77 [accessed 2019 Sep 26]. http://www.ncbi.nlm.nih.gov/pubmed/18703743.
   PubMed Web of Science ®Google Scholar
• Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. [Internet]. 2009;1:539–47. doi:10.4161/mabs.1.6.10015.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol [Internet]. 2015;16:57–66. [accessed 2019 Sep 26]. http://www.ncbi.nlm.nih.gov/pubmed/25524800.
   PubMed Web of Science ®Google Scholar
• Liu H, Saxena A, Sidhu SS, Wu D. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol [Internet]. 2017;8:38 [accessed 2019 Sep 26]. http://www.ncbi.nlm.nih.gov/pubmed/28184223.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95–106. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies; different formats. Drug Discov Today. [Internet]. 2015;20(7):838–47. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs. 2010;2(3):309–19. doi:10.4161/mabs.2.3.11791.
   PubMed Web of Science ®Google Scholar
• Wang Z, Kim GB, Woo JH, Yuan YL, Mathias A, Stavrou S, Neville DM. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Bioconjug Chem. 2007;18(3):947–55. doi:10.1021/bc0603438.
   PubMed Web of Science ®Google Scholar
• Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, Stafford RL, Steiner AR, Sato AK, Hallam TJ, et al. Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system. MAbs. 2015;7(1):231–42. doi:10.4161/19420862.2015.989013.
   PubMed Web of Science ®Google Scholar
• Dickopf S, Lauer ME, Ringler P, Spick C, Kern P, Brinkmann U. Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. Biol Chem. 2018;400(3):343–350.
   Web of Science ®Google Scholar
• Ying T, Jung ST, Kontermann RE, Kim Y-S, Ha J-H, Kim J-E. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Proteins Front Immunol [Internet]. 2016;7:394 [accessed 2020 Jan 16]. www.frontiersin.org.
   PubMed Web of Science ®Google Scholar
• Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.
   Web of Science ®Google Scholar
• Yu L, Wang J. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances. J Cancer Res Clin Oncol. 2019;145(4):941–56. doi:10.1007/s00432-019-02867-6.
   PubMed Web of Science ®Google Scholar
• Chanier T, Chames P. Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer. Antibodies. 2019;8(1):13. doi:10.3390/antib8010013.
   Web of Science ®Google Scholar
• Seifert O, Rau A, Beha N, Richter F, Kontermann RE. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. MAbs. 2019;11(5):919–29. doi:10.1080/19420862.2019.1603024.
   PubMed Web of Science ®Google Scholar
• Kwon NY, Kim Y, Lee JO. Structural diversity and flexibility of diabodies. Methods. 2019;154:136–42. doi:10.1016/j.ymeth.2018.09.005.
   PubMed Web of Science ®Google Scholar
• Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. [Internet]. 2013;9(4):527–39. doi:10.2217/fon.12.203.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015;67(2):58–66. doi:10.1016/j.molimm.2015.02.033.
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. [Internet]. 2009;69(12):4941–44. doi:10.1158/0008-5472.CAN-09-0547.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol. [Internet]. 2014;41(5):653–60. doi:10.1053/j.seminoncol.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor. Cancer Res. 2009;69(10):4270–76. doi:10.1158/0008-5472.CAN-08-2861.
   PubMed Web of Science ®Google Scholar
• Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res [Internet]. 2006;12:3085–91. [accessed 2019 Sep 26]. http://www.ncbi.nlm.nih.gov/pubmed/16707606.
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. [Internet]. 2012;11(3):582–93. doi:10.1158/1535-7163.MCT-11-0820.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141,an IGF-IR-and ErbB3-directed bispecific antibody overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014;13(2):410–25. doi:10.1158/1535-7163.MCT-13-0255.
   PubMed Web of Science ®Google Scholar
• Duligotuzumab CP. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy. Drugs Future. 2015;40(3):167. doi:10.1358/dof.2015.040.03.2312450.
   Web of Science ®Google Scholar
• Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. [Internet]. 2013;19(24):6730–40. doi:10.1158/1078-0432.CCR-13-0081.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Pollara J, Tomaras GD, Haynes BF. Humoral and innate antiviral immunity as tools to clear persistent HIV infection. J Infect Dis. 2017;215(suppl_3):S152–9. doi:10.1093/infdis/jiw555.
   PubMedGoogle Scholar
• Viale G. HER2 in breast cancer: ESMO biomarker factsheet | oncologyPRO [Internet] [ accessed 2019 Sep 26]. https://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/HER2-in-Breast-Cancer.
   Google Scholar
• Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1): S3–S8.
   Web of Science ®Google Scholar
• Ferreira PMP, Pessoa C. Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges. Brazilian J Pharm Sci. 2017;53(2):e16076.
   Web of Science ®Google Scholar
• National Cancer Institute (NIH). HER2 genetic link to breast cancer – National Cancer Institute [Internet] [ accessed 2019 Sep 26]. https://www.cancer.gov/research/progress/discovery/her2.
   Google Scholar
• Duffy MJ. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci. [Internet]. 2006;43:325–47. doi:10.1080/10408360600739218.
   PubMed Web of Science ®Google Scholar
• Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol. [Internet]. 2015;418 Pt 3:245–63. doi:10.1016/j.mce.2015.06.004.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Hormone therapy for breast cancer | American Cancer Society [Internet] [ accessed 2019 Sep 27]. https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html.
   Google Scholar
• Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011;6:359–69. doi:10.1586/eem.11.25.
   PubMedGoogle Scholar
• Lim E, Palmieri C, Tilley WD. Renewed interest in the progesterone receptor in breast cancer. Br J Cancer. 2016;115:909–11. doi:10.1038/bjc.2016.303.
   PubMed Web of Science ®Google Scholar
• Ratini M. Types of breast cancer: triple negative, ER-positive, HER2-positive [Internet] [ accessed 2019 Sep 27]. https://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive#1.
   Google Scholar
• Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. doi:10.1002/jcb.10661.
   PubMed Web of Science ®Google Scholar
• Li Y, Cozzi PJ, Russell PJ. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev [Internet]. 2010;30:67–101 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/19536865.
   PubMed Web of Science ®Google Scholar
• Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res [Internet]. 1997;57:3629–34 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/9288760.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer [Internet]. 2019;125:2561–69 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/31012963.
   PubMed Web of Science ®Google Scholar
• Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol. [Internet]. 1998;159:2041–46. discussion 2046-7. doi:10.1016/S0022-5347(01)63239-7.
   PubMed Web of Science ®Google Scholar
• Somoza JR, Ho JD, Luong C, Ghate M, Sprengeler PA, Mortara K, Shrader WD, Sperandio D, Chan H, McGrath ME, et al. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Structure [Internet]. 2003;11:1123–31 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/12962630.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Wu Q, Peng J, Ruan Y, Gu J. Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2α phosphorylation in prostate cancer. Cell Signal. [Internet]. 2015;27:789–97. doi:10.1016/j.cellsig.2014.12.020.
   PubMed Web of Science ®Google Scholar
• Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. [Internet]. 2004;6:185–95. doi:10.1016/j.ccr.2004.07.008.
   PubMed Web of Science ®Google Scholar
• Barwe SP, Maul RS, Christiansen JJ, Anilkumar G, Cooper CR, Kohn DB, Rajasekaran AK. Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol [Internet]. 2007;30:899–904 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/17332929.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Cancer [Internet]. [ accessed 2019 Sep 26]. https://www.who.int/health-topics/cancer#tab=tab_1.
   Google Scholar
• Ganesan R, Zhang Y, Landgraf KE, Lin SJ, Moran P, Kirchhofer D. An allosteric anti-hepsin antibody derived from a constrained phage display library. Protein Eng Des Sel. 2012;25:127–33. doi:10.1093/protein/gzr067.
   PubMed Web of Science ®Google Scholar
• Spasevska I, Master. An outlook on bispecific antibodies: methods of production and therapeutic benefits. BioSciences Master Reviews; 2014.
   Google Scholar
• Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol. [Internet]. 2017;6:12. doi:10.1186/s40164-017-0072-7.
   PubMed Web of Science ®Google Scholar
• Yang F, Wen W, Qin W. Bispecific antibodies as a development platform for new concepts and treatment strategies. Int J Mol Sci [Internet]. 2016;18 [accessed 2019 Sep 27]. http://www.ncbi.nlm.nih.gov/pubmed/28036020.
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Sanders RW. Opposites attract in bispecific antibody engineering. J Biol Chem. [Internet]. 2017;292:14718–19. doi:10.1074/jbc.H117.793497.
   PubMed Web of Science ®Google Scholar